AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Fresh off a global deal to in-license a novel oncology molecule discovered in China, the head of strategy for AZ’s Oncology Innovative Medicine Unit speaks with PharmAsia News during the JP Morgan Healthcare Conference about how AstraZeneca’s strategy in Asia differs from its peers.